Cellectis (CLLS) Stock Rating Lowered by ValuEngine

Cellectis (NASDAQ:CLLS) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

Several other analysts have also recently commented on CLLS. Zacks Investment Research cut Cellectis from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Jefferies Group reiterated a “buy” rating and set a $47.00 price target on shares of Cellectis in a research report on Tuesday, September 26th. BidaskClub raised Cellectis from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. SunTrust Banks reissued a “hold” rating and set a $20.00 price objective on shares of Cellectis in a research note on Friday, October 6th. Finally, Nomura lowered their price objective on Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $39.29.

Shares of Cellectis (NASDAQ:CLLS) traded down $0.36 on Friday, hitting $24.57. The company had a trading volume of 206,660 shares, compared to its average volume of 211,332. Cellectis has a 52-week low of $16.32 and a 52-week high of $35.07.

Several institutional investors have recently made changes to their positions in CLLS. Sphera Funds Management LTD. lifted its stake in shares of Cellectis by 27.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock valued at $5,261,000 after purchasing an additional 44,100 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Cellectis by 132.1% during the 2nd quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 5,435 shares in the last quarter. ARK Investment Management LLC lifted its stake in Cellectis by 79.1% during the 2nd quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,784 shares in the last quarter. Balyasny Asset Management LLC acquired a new position in Cellectis during the 2nd quarter worth about $719,000. Finally, Williams Jones & Associates LLC acquired a new position in Cellectis during the 2nd quarter worth about $244,000. 16.60% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/03/cellectis-clls-stock-rating-lowered-by-valuengine.html.

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply